Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gastroesophageal Reflux Disease
Intervention: Esomeprazole (Drug); Esomeprazole (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s): Paula Fernstrom, Study Director, Affiliation: Nexium Global Product Director, AstraZeneca
Summary
The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered
orally compared to intravenously on the maximum acid output in subjects with symptoms of
Gastroesophageal reflux disease (GERD).
Clinical Details
Official title: An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To compare the maximum acid output during pentagastrin stimulation after 10 days of Nexium dosing administered orally with 10 days dosing via intravenous administration.
Secondary outcome: To compare basal acid output at steady state and when switching between Oral and IV adminstration of Nexium.To compare maximum acid output when switching between Oral and IV adminstration of Nexium Safety assessment via adverse event recording
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Heartburn on 2 out of the last 7 days prior to screening or a diagnosis of GERD (with
or without a diagnosis of Erosive eosphagitis).
- Body Mass Index within the limits specified in the protocol
Exclusion Criteria:
- History of esophageal, duodenal or gastric surgery
- History of severe liver disease.
- Any other significant disease or pathology judged to be clinically significant by the
investigator
Locations and Contacts
Additional Information
Starting date: September 2002
Last updated: January 21, 2011
|